• 00 atmail

Queensland company to take breast cancer medical device to world

Wednesday, 12 November 2008
Queensland company to take breast cancer medical device to world

13 November, 2008 - Brisbane medical device company ImpediMed will showcase its revolutionary technology designed to help cancer survivors at the annual Innovation Shoot Out in San Francisco in January next year.

Tourism, Regional Development and Industry Minister Desley Boyle today announced the State Government-funded company would represent Queensland in the prestigious event as part of the G'Day USA/Australia Week 2009 celebrations in the United States.

"This innovative Smart Queensland company received $115,000 from the Government to help develop and then obtain regulatory approval from the United States Food and Drug Administration for the L-Dex U400 device," Ms Boyle said.

"It has been demonstrated to accurately early detect the painful condition Lymphoedema, or fluid build-up in the arms of breast cancer survivors.

"It does this by passing a low frequency current through the limbs to measure and compare the extra cellular fluid levels.

"Medical pro fessionals are using this device to assess and detect this unfortunate side-effect of breast cancer surgery at the earliest possible stage.

"The condition can be treated if detected early enough which is fantastic news for women recovering from both the physical and emotional effects of breast cancer.

"Lymphoedema currently affects more than 100,000 recovering from breast cancer in Australia alone and millions worldwide."

Queensland Trade Minister John Mickel said the Innovation Shoot Out on 15 January was sponsored by the State Government to help Queensland businesses crack the US market.

"This is the third year that Australian companies will take part in the Shoot Out and be judged before a panel of US venture capitalists and private equity business leaders," he said.

"It is a major event for Queensland business and one which could open many doors to the lucrative US market.

"Last year's Queensland representative, Biolytix Wa ter, the developers of the innovative Biolytix Wastewater System, met with three potential US licensees who they are still in discussion with."

ImpediMed CEO Greg Brown said the company was honoured to be chosen to represent Queensland at the Innovative Shoot Out.

"It has been an exciting year for the company already," he said.

"We recently received clearance from the United States Food and Drug Administration for the L-Dex U400 which paves the way for us to directly launch the device into the US market.

"Winning next year's Innovation Shoot Out would provide us with even more opportunities to market this important new technology."

Mr Brown said the company was very grateful for State Government assistance in recent years.

"The funding we have received has enabled us to develop the L-Dex U400 in collaboration with researchers from the Queensland University of Technology and the University of Queensland," he said.

"We we re also extremely pleased to meet with Queensland Premier Anna Bligh when she opened our company's new San Diego office in July this year."